logo
Altru Health System honored with Grand Forks EDC's Klaus Thiessen Impact Award

Altru Health System honored with Grand Forks EDC's Klaus Thiessen Impact Award

Yahoo28-03-2025

Mar. 27—GRAND FORKS — The Grand Forks Region Economic Development Corporation on Thursday honored Altru Health System with its Klaus Thiessen Impact Award.
The health care provider received the award at the outset of the EDC's annual meeting in front of approximately 275 people at the Alerus Center ballroom.
"We really felt they had risen to the top with the new hospital and all their contributions to the community," EDC CEO and President Keith Lund told the Herald.
Altru's crowning achievement this year has been its brand-new $500 million hospital in Grand Forks. The health care provider is also in the process of acquiring CHI St. Alexius Health hospital in Devils Lake.
Altru CEO Todd Forkel, President Josh Deere and the Altru Foundation's Chief Partnership and Philanthropy Officer Kristi Hall-Jiran were on hand to receive the award, named for the EDC's retired longtime CEO.
Forkel told Lund the provider was "humbled and really grateful" to receive the award, and thanked Altru's many employees for their work.
"We really look at it as a privilege to be able to not only serve Grand Forks, but the greater Grand Forks area," Forkel said.
Altru moved out of its 52-year-old home and into its new facility next door in January. Lund presented the Altru executives with a painting by Eric Castle, depicting generations of Grand Forks hospitals, with the latest addition towering over the other two.
Prompted by Lund, Deere said the new hospital made Grand Forks into a medical destination and was a tool for bringing more workers to Grand Forks.
"We have a huge recruiting tool right now," Deere said. "We have the most state-of-the-art hospital in the Midwest."
Thursday's event also served as an opportunity for Lund and Director of Workforce Development Becca Cruger to highlight growth and success in Grand Forks.
Highlights included Belgian potato processor Agristo's plans to open a $450 million plant in Grand Forks, the temporary bed-down of the 28th Bomb Wing at Grand Forks Air Force Base (Lund: "If you think that isn't economic development, ask any hotel owner in Grand Forks") and UND's third-largest class of all time.
"That is your future workforce," Cruger said as a picture of the class of 2028 flashed onscreen.
Discussing Grand Forks Public Schools' soon-to-open Career Impact Academy, Hall-Jiran reminded Lund of his fundraising request that helped bring the career and technical education center to fruition.
"I remember that phone call, Keith," Hall-Jiran told Lund. "You did a great job of asking for a million dollars."
EDC primary sector businesses continued to report 10-year increases in employment, average salary and payroll.
Payroll from EDC client businesses added $645 million to the region, Lund said, plus another $216 million in company spending, adding up to a regional combined impact of $861 million for the region.
The theme of Thursday's event was "Plant and Prosper," in reference to Grand Forks' origins as an agricultural community.
"We would not be here as a community, in the fashion we're in, without the agricultural community that supports Grand Forks," EDC Board Chair Shawn Gaddie said.
In an acknowledgment of the theme, Gaddie presented past chair John Oncken with a painting of a tractor in a field, rendered in the style of Vincent Van Gogh's "Starry Night."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Belgian beer exports decline again in 2024
Belgian beer exports decline again in 2024

Yahoo

timea day ago

  • Yahoo

Belgian beer exports decline again in 2024

Belgium's brewing sector saw beer volumes drop again last year, both at home and globally, new figures from a local trade body show. Total export volumes dropped 3.4% in 2024 to 14.5m hectolitres according to the industry association Belgian Brewers' annual report. Within the EU, exports declined by 2.6% to 12.4m hectolitres, while exports outside the EU saw an 8% decrease to roughly 2m hectolites. Despite the challenges, the trade body said that Belgian beer continues to be a 'popular' export product, with 70% of production sold internationally. The dip is a slight improvement on 2023 figures, when the sector booked a 7.5% drop in export volumes at 15m hectolitres. Domestic consumption meanwhile dropped 2.1% to 6.39m hectolitres. Beer sales in Belgium's hospitality sector fell by 2.9%, while supermarket sales saw a 1.5% decrease. Despite the dip, it was also improvement on the 6% drop in domestic consumption recorded in 2023. Trade body director Krishan Maudgal said: "The figures are down, but less sharply than in 2023. However, we cannot yet speak of a real turnaround in the trend. Stability and a predictable business climate are essential to ensure a sustainable future for our sector.' Belgium's brewing sector however is witnessing a "structural decline" in its domestic market, Belgian Brewers said, with overall consumption in the country having nearly 20% "over a ten-year period". "The persistent pressure on purchasing power, rising costs, and the uncertain geopolitical context are clearly reflected in the annual figures," the trade body said. In 2024, six breweries shuttered their doors, reducing the total number of breweries to 411 by the year's end. The brewing sector continues to be an 'important driver' to the Belgian economy, Belgian Brewers said, contributing €4bn or approximately 1% of the country's GDP, according to the country's Federal Planning Bureau. Alongside the release of its 2024 annual report, Belgian Brewers called on policymakers "to strengthen the stability and predictability of the business environment", in order "to ensure continued investment in innovation, sustainability, and quality". "Belgian beer exports decline again in 2024" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP

Yahoo

time2 days ago

  • Yahoo

Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP

TORONTO & MONTREAL, June 11, 2025--(BUSINESS WIRE)--Genesys Capital ("Genesys") is pleased to announce the upcoming closing of Genesys Ventures IV LP ("Fund IV" or the "fund") to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. ​ Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. ​These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. ​ Quotes "EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund."Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation."Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors."Senia Rapisarda, Managing Director, HarbourVest Partners. "It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations."Damian Lamb, Co-founder and Managing Director, Genesys Capital. "We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership."Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. "Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete."The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada. Contact: Genesys Capital 123 Front Street West, Suite 1503, Toronto, ON M5J 2M2 ​ info@ View source version on Contacts Jennifer Williamsjen@ (416) 598-4900

Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP

Yahoo

time2 days ago

  • Yahoo

Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP

TORONTO & MONTREAL, June 11, 2025--(BUSINESS WIRE)--Genesys Capital ("Genesys") is pleased to announce the upcoming closing of Genesys Ventures IV LP ("Fund IV" or the "fund") to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. ​ Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. ​These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. ​ Quotes "EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund."Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation."Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors."Senia Rapisarda, Managing Director, HarbourVest Partners. "It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations."Damian Lamb, Co-founder and Managing Director, Genesys Capital. "We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership."Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. "Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete."The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada. Contact: Genesys Capital 123 Front Street West, Suite 1503, Toronto, ON M5J 2M2 ​ info@ View source version on Contacts Jennifer Williamsjen@ (416) 598-4900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store